Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

NCT01402440 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated due to enrolment challenges and availability of other options for DLBCL patients. The termination is not a consequence of any safety concern.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals